Clinical Trial Update: Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial in ALK-positive non-small cell lung cancer evaluates the activity of lorlatinib in relation to ALK resistance mutations detected in blood.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING